Authors:
Address: University of California, San Francisco, 94143-0622, USA. dongb@pharmacy.ucsf.edu
Journal:

Publication:

abstract

OBJECTIVES:

To estimate Nevirapine (NVP) pharmacokinetics and examine its association with rash and/or hepatotoxicity in women starting antiretroviral treatment in the AIDS Clinical Trials Group A5208/OCTANE study in Africa.

DESIGN:

In HIV-infected, nonpregnant women with screening CD4 cell count less than 200 cells/μl randomized to NVP (twice daily, after 14-day once-daily lead-in period) and tenofovir/emtricitabine, single NVP blood samples were collected 14 and 28 days following randomization. Rash and hepatotoxicity that occurred during therapy, or within 7 days after the last dose of NVP, were defined as toxicity.

METHODS:

NVP pharmacokinetics were modeled by population pharmacokinetic analysis. Individual Bayesian pharmacokinetic estimates were used to calculate clearance, 24-h area under the curve, and predicted plasma concentrations.

RESULTS:

Median week 4 NVP clearance was 2 l/h. among the 359 women, 194 (54%) developed a rash of any grade; 82 (23%) had grade 2+ and nine (3%) had grade 3+ rash. Median clearance was 1.7 l/h for participants exhibiting 3+ rash versus 2 l/h in women without 3+ rash (P = 0.046). The odds of developing 3+ rash was 50% higher for every 20% decrease in clearance (P = 0.046). NVP discontinuation due to rash/liver toxicity was significantly more common among women with pretreatment CD4 cell count more than 250 cells/μl (P = 0.003).

CONCLUSION:

In this study, HIV-infected African women starting a NVP-based antiretroviral regimen had a lower NVP clearance compared to previous reports. Severe rash, but not hepatotoxicity, was associated with higher NVP exposure. Albeit observed in a small number of women, baseline CD4 cell count at least 250 cells/μl was significantly associated with NVP toxicity.

Related Articles
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Antivir Ther. 2005
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, et al. Antivir Ther. 2005; 10(4):489-98.
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
HIV Med. 2007
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N, Apornpong T, Teeratakulpisarn S, Chaithongwongwatthana S, Taweepolcharoen C, Mangclaviraj S, Limpongsanurak S, Jadwattanakul T, Eiamapichart P, Luesomboon W, et al. HIV Med. 2007 Sep; 8(6):357-66.
Nevirapine-Associated Hepatotoxicity and Rash among HIV-Infected Pregnant Women in Kenya.
J Int Assoc Physicians AIDS Ca...
Nevirapine-Associated Hepatotoxicity and Rash among HIV-Infected Pregnant Women in Kenya.
Peters PJ, Polle N, Zeh C, Masaba R, Borkowf CB, Oyaro B, Omolo P, Ogindo P, Ndivo R, Angira F, et al. J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr; 11(2):142-9. Epub 2011 Oct 21.
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Drugs. 2003
Review Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS, Goa KL. Drugs. 2003; 63(8):769-802.
Review Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Cochrane Database Syst Rev. 2006
Review Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW. Cochrane Database Syst Rev. 2006 Apr 19; (2):CD004535. Epub 2006 Apr 19.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster